First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17-Reference-Cited by-同舟云学术

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Published:2024-02 Issue: Volume: Page:113600
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Mark Michael,Froesch Patrizia,Gysel Katrin,Rothschild Sacha I.,Addeo Alfredo,Ackermann Christoph J.,Chiquet Sabrina,Schneider Martina,Ribi Karin,Maranta Angela Fischer,Bastian Sara,von Moos Roger,Joerger Markus,Früh Martin

Funder

Astra Zeneca R&D Osaka

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J Clin Oncol,2019

2. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC;Spigel;Ann Oncol,2019

3. Hendriks L.E., Kerr K.M., Menis J., Mok T.S., Nestle U., Passaro A., Peters S., Planchard D., Smit E.F., Solomon B.J., Veronesi G., Reck M.. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Published: January 17, 2023. https://doi.org/10.1016/j.annonc.2022.12.013.

4. Govindan R., Garfield D.H.. Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol 31(Suppl 11): 27–31. https://doi.org/10.1053/j.semin oncol.2004.10.006.

5. Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials;Gebbia;Ann Oncol,2005